US Nuclear Corp. Announces Third Quarter 2023 Results
US Nuclear Corp. Announces Third Quarter 2023 Results
LOS ANGELES, CA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –US Nuclear Corp. (OTC-QB: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the third quarter ended September 30, 2023.
加利福尼亚州洛杉矶，2023年11月29日（GLOBE NEWSWIRE）——通过NewMediaWire——先进辐射、化学和生物探测以及无人机仪器的领先制造商美国核公司（场外交易代码：UCLE）最近公布了截至2023年9月30日的第三季度财务业绩。
For the three months ended September 30, 2023:
在截至2023年9月30日的三个月中：
- Sales were $593,502 compared to $617,434 for the same period in 2022
- Cost of goods decreased by a factor of 3 compared to the same period in 2022, from 66% to only 22%
- Gross margins increased by 44.15% due to a mix of enhanced manufacturing efficiency and higher margin products sold during the period. The Company expects this trend to continue due to increased sales of US Nuclear's premium highly valued, specialized products.
- Selling, general and administrative expenses were $539,339 compared to $695,381 for the same period in 2022, a decrease of $156,042 or 28.93%
- Loss from operations decreased by a factor of 7 and was $73,562 compared to $483,419 for the same period in 2022
- Net loss was $760,062 compared to $655,822 for the same period in 2022
- 销售额为593,502美元，而2022年同期为617,434美元
- 与2022年同期相比，商品成本下降了3倍，从66％降至仅22％
- 毛利率增长了44.15％，这要归因于在此期间销售的制造效率提高和利润率更高的产品。该公司预计，由于US Nuclear的高价值专业产品的销售增加，这种趋势将持续下去。
- 销售、一般和管理费用为539,339美元，而2022年同期为695,381美元，下降了156,042美元，下降了28.93％
- 运营亏损下降了7倍，为73,562美元，而2022年同期为483,419美元
- 净亏损为760,062美元，而2022年同期为655,822美元
Robert Goldstein, CEO of US Nuclear Corp., commented:
"We are pleased to report another quarter of strong performance. The results underscore our team's commitment to driving sales revenue while reducing expenses on our path to profitability, and our ability to capitalize on the increasing demand for our innovative radiation detection solutions. We drastically increased our gross margins by 44.15% by streamlining our production and manufacturing efficiency and by selling our specialized products to buyers willing to pay for our premium product quality and functionality. We expect this trend to continue and a ramp-up in sales revenue will translate into profitable operating income. The launch of several unique new chemical detectors for detecting drugs (fentanyl), explosives, chemical warfare agents and even PFAS "forever chemicals" will be a sales catalyst moving forward, in addition to increased demand for our tritium monitoring instrumentation which is direly needed as fusion power research and operation ramps up."
美国核公司首席执行官罗伯特·戈德斯坦评论说：
“我们很高兴地报告又一个季度的强劲表现。这些结果突显了我们的团队致力于提高销售收入，同时减少盈利道路上的开支，以及我们利用对创新辐射探测解决方案不断增长的需求的能力。通过简化生产和制造效率以及向愿意为我们的优质产品质量和功能付费的买家销售我们的专业产品，我们将毛利率大幅提高了44.15％。我们预计这种趋势将继续下去，销售收入的增加将转化为可盈利的营业收入。几款用于检测药物（芬太尼）、炸药、化学战剂甚至全氟辛烷磺酸 “永久化学品” 的独特的新化学探测器的推出将成为未来的销售催化剂，此外对我们的锶监测仪器的需求也将增加，随着聚变能研究和运营的加强，这种需求是迫切需要的。”
| US NUCLEAR CORP. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (unaudited) | ||||||||||
| Three Months Ended | ||||||||||
| September 30, | ||||||||||
| 2023 | 2022 | |||||||||
| Sales | $593,502 | $617,434 | ||||||||
| Cost of sales | 127,727 | 22% | 405,471 | 66% | ||||||
| Gross profit | 465,775 | 78% | 211,963 | 34% | ||||||
| Operating expenses | ||||||||||
| Selling, general and administrative expenses | 539,337 | 695,381 | ||||||||
| Total operating expenses | 539,337 | 695,381 | ||||||||
| Loss from operations | 73,562 | 15% | 483,419 | ) | ||||||
| Other income (expense) | ||||||||||
| Interest expense | (27,795 | ) | (31,710 | ) | ||||||
| Equity loss in investment | - | - | ||||||||
| Loss on deconsolidation | - | - | ||||||||
| Amortization of debt discount | (658,705 | ) | (140,693 | ) | ||||||
| Total other income (expense) | (686,500 | ) | (172,403 | ) | ||||||
| Loss before provision for income taxes | (760,062 | ) | (655,822 | ) | ||||||
| Provision for income taxes | - | - | ||||||||
| Net loss | $(760,062 | ) | $(655,822 | ) | ||||||
| Deemed dividend for down-round provision in warrants | - | - | ||||||||
| Net loss attributed to common stockholders | $(760,062 | ) | $(655,822 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 36,237,707 | 29,504,433 | ||||||||
| Loss per shares - basic and diluted | $(0.02 | ) | $(0.02 | ) | ||||||
| The accompanying notes are an integral part of these | ||||||||||
| unaudited condensed consolidated financial statements. | ||||||||||
| US NUCLEAR CORP. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (unaudited) | ||||||||||
| Nine Months Ended | ||||||||||
| September 30, | ||||||||||
| 2023 | 2022 | |||||||||
| Sales | $1,588,009 | $1,539,517 | ||||||||
| Cost of sales | 651,992 | 837,523 | ||||||||
| Gross profit | 936,017 | 701,994 | ||||||||
| Operating expenses | ||||||||||
| Selling, general and administrative expenses | 1,875,583 | 2,103,637 | ||||||||
| Total operating expenses | 1,875,583 | 2,103,637 | ||||||||
| Loss from operations | (939,565 | ) | (1,401,644 | ) | ||||||
| Other income (expense) | ||||||||||
| Interest expense | (70,635 | ) | (37,650 | ) | ||||||
| Equity loss in investment | (8,059 | ) | - | |||||||
| Loss on deconsolidation | (2,539 | ) | - | |||||||
| Amortization of debt discount | (1,275,316 | ) | (232,449 | ) | ||||||
| Total other income (expense) | (1,356,549 | ) | (270,099 | ) | ||||||
| Loss before provision for income taxes | (2,296,114 | ) | (1,671,743 | ) | ||||||
| Provision for income taxes | - | - | ||||||||
| Net loss | $(2,296,114 | ) | $(1,671,743 | ) | ||||||
| Deemed dividend for down-round provision in warrants | (2,013 | ) | (9,652 | ) | ||||||
| Net loss attributed to common stockholders | $(2,298,127 | ) | $(1,681,395 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 35,049,921 | 28,923,132 | ||||||||
| Loss per shares - basic and diluted | $(0.07 | ) | $(0.06 | ) | ||||||
| 美国核公司和子公司 | ||||||||||
| 简明合并运营报表 | ||||||||||
| （未经审计） | ||||||||||
| 三个月已结束 | ||||||||||
| 9月30日 | ||||||||||
| 2023 | 2022 | |||||||||
| 销售 | 593,502 美元 | 617,434 美元 | ||||||||
| 销售成本 | 127,727 | 22% | 405,471 | 66% | ||||||
| 毛利润 | 465,775 | 78% | 211,963 | 34% | ||||||
| 运营费用 | ||||||||||
| 销售、一般和管理费用 | 539,337 | 695,381 | ||||||||
| 运营费用总额 | 539,337 | 695,381 | ||||||||
| 运营损失 | 73,562 | 15% | 483,419 | ) | ||||||
| 其他收入（支出） | ||||||||||
| 利息支出 | (27,795) | ) | (31,710) | ) | ||||||
| 投资中的股权损失 | - | - | ||||||||
| 拆除合并造成的损失 | - | - | ||||||||
| 债务折扣的摊销 | (658,705) | ) | (140,693) | ) | ||||||
| 其他收入总额（支出） | (686,500) | ) | (172,403) | ) | ||||||
| 所得税准备金前的亏损 | (760,062) | ) | (655,822) | ) | ||||||
| 所得税准备金 | - | - | ||||||||
| 净亏损 | $ (760,062) | ) | $ (655,822) | ) | ||||||
| 认股权证下行准备金的视为分红 | - | - | ||||||||
| 归因于普通股股东的净亏损 | $ (760,062) | ) | $ (655,822) | ) | ||||||
| 加权平均已发行股票——基本股和摊薄后股票 | 36,237,707 | 29,504,433 | ||||||||
| 每股亏损——基本亏损和摊薄亏损 | $ (0.02) | ) | $ (0.02) | ) | ||||||
| 随附的注释是这些注释不可分割的一部分 | ||||||||||
| 未经审计的简明合并财务报表。 | ||||||||||
| 美国核公司和子公司 | ||||||||||
| 简明合并运营报表 | ||||||||||
| （未经审计） | ||||||||||
| 九个月已结束 | ||||||||||
| 9月30日 | ||||||||||
| 2023 | 2022 | |||||||||
| 销售 | 1,588,009 美元 | 1,539,517 美元 | ||||||||
| 销售成本 | 651,992 | 837,523 | ||||||||
| 毛利润 | 936,017 | 701,994 | ||||||||
| 运营费用 | ||||||||||
| 销售、一般和管理费用 | 1,875,583 | 2,103,637 | ||||||||
| 运营费用总额 | 1,875,583 | 2,103,637 | ||||||||
| 运营损失 | (939,565) | ) | (1,401,644) | ) | ||||||
| 其他收入（支出） | ||||||||||
| 利息支出 | (70,635) | ) | (37,650 | ) | ||||||
| 投资中的股权损失 | (8,059 | ) | - | |||||||
| 拆除合并造成的损失 | (2,539 | ) | - | |||||||
| 债务折扣的摊销 | (1,275,316 | ) | (232,449) | ) | ||||||
| 其他收入总额（支出） | (1,356,549) | ) | (270,099 | ) | ||||||
| 所得税准备金前的亏损 | (2,296,114 | ) | (1,671,743 | ) | ||||||
| 所得税准备金 | - | - | ||||||||
| 净亏损 | $ (2,296,114 | ) | $ (1,671,743) | ) | ||||||
| 认股权证下行准备金的视为分红 | (2,013) | ) | (9,652) | ) | ||||||
| 归因于普通股股东的净亏损 | $ (2,298,127 | ) | $ (1,681,395) | ) | ||||||
| 加权平均已发行股票——基本股和摊薄后股票 | 35,049,921 | 28,923,132 | ||||||||
| 每股亏损——基本亏损和摊薄亏损 | $ (0.07 | ) | $ (0.06 | ) | ||||||
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
《安全港法》
本新闻稿包括1995年《美国私人证券诉讼改革法》安全港条款所指的 “前瞻性陈述”。实际结果可能与预期、估计和预测不同，因此，您不应依赖这些前瞻性陈述作为对未来事件的预测。诸如 “期望”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“将”、“可以”、“应该”、“相信”、“预测”、“潜力”、“继续” 等词语以及类似的表达方式旨在识别此类前瞻性陈述。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与预期结果存在重大差异。
Investors may find additional information regarding US Nuclear Corp. at the SEC website at or the company's website at
投资者可以在美国证券交易委员会网站或该公司的网站上找到有关美国核公司的更多信息
CONTACT:
US Nuclear Corp. (OTC-QB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Michael Hastings, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com
联系人：
美国核公司（OTC-QB：UCLE）
罗伯特·戈德斯坦，总裁、首席执行官兼董事长
迈克尔·黑斯廷斯，首席财务官
(818) 883 7043
电子邮件：info@usnuclearcorp.com